THE CUNNINGHAM PANEL™ - Autoantibody testing for neuropsychiatric symptoms

There is a growing body of scientific evidence documenting the connection between infection, inflammation, immune dysfunction and the development of neurologic and psychiatric illnesses.

The Cunningham Panel™ helps clinicians identify whether a patient’s neurologic and/or psychiatric symptoms may be due to an infection-triggered basal ganglia encephalitis (BGE), which includes autoimmune neuropsychiatric syndromes such as PANS/PANDAS. Symptoms of BGE can mimic various mental illnesses.

The Cunningham Panel measures circulating levels of autoantibodies attacking brain receptors, as well as autoantibodies that stimulate the production of neurotransmitters in the basal ganglia. These interactions have the potential to disrupt neuronal functioning and can impact movement, behaviour and cognition. These test results can support a physician’s clinical diagnosis with laboratory evidence of an underlying autoimmune dysfunction, and assist the physician in determining an appropriate treatment regimen.

The Cunningham Panel™ is a metabolic test, the laboratory results represent the values at the time the patient’s blood was collected, which may vary over time, with treatment, and in conjunction with the presence or absence of symptoms. This panel is composed of 5 tests: Anti-Dopamine D1 Receptor, Anti-Dopamine D2L Receptor, Anti-Lysoganglioside-GM1, Anti-Tubulin and Calcium/calmodulin-dependent protein kinase II (CaMKII). First four of the tests measure the levels of circulating autoantibodies in serum that are directed against and bind to, or block specific neuronal targets in the brain. Each of these autoantibody targets (Dopamine D1 and D2L receptors,

Lysoganglioside-GM1 and Tubulin) have been associated with the presence of various neurologic and/or psychiatric symptoms. The last one, the CaMKII test is a cell stimulation assay. It measures the ability of a patient’s autoantibodies to stimulate the CaMKII enzyme in human brain cells. The CaMKII is involved in upregulating the production of neurotransmitters – dopamine, epinephrine, and norepinephrine and elevated levels of CaMKII activity correlated with certain adrenergic symptoms (these include nerve cells in which certain neurotransmitters activate), as well as the likelihood of an active infection or reinfection.

When autoantibodies bind to or block these targets, they can disrupt normal neuronal functioning, resulting in the onset of neuropsychiatric symptoms. Elevated levels on one or more of these tests indicate that a person’s neuropsychiatric symptoms may be due to a treatable autoimmune disorder (triggered by an infection(s), rather than a classic neurologic or psychiatric illness.

A link to the list of peer-reviewed journal articles by world-renowned researchers and clinicians investigating infection-induced autoimmune neurologic disorders.

The Cunningham Panel™ is unique and based on over two decades of research. It is offered exclusively through Moleculera Labs, Inc. and has been utilized by clinicians worldwide.

For European customers (outside UK, Ireland, Poland, Ukraine) this unique test is now available through R.E.D. Laboratories.

Please contact us at for further details and/or to order the kit. Moleculera Labs offers a wide range of training material and personalized guidance for practitioners.

Most recent posts

Sign up for the newsletter and be the first to know about our latest news!

Staff pick

How can we help you?

We are happy to answer all your questions. Would you like more information about our products or training courses? Our customer service will be happy to help you!